Dr Nabil Saba emphasizes that while systemic therapy has revolutionized the treatment of anaplastic thyroid cancer (ATC), ...
Development of mixed histiocytosis (Langerhans cell histiocytosis (LCH))/Erdheim–Chester disease (ECD)) after treatment in patients with an initial skull LCH lesion has not been well recognized. An ...
Pediatric low-grade gliomas (pLGGs) exhibit distinct biological and clinical characteristics compared to adult gliomas, and their treatment strategies differ substantially from those used in adults.
Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for ...
Mixed histiocytosis (Langerhans cell histiocytosis [LCH] / Erdheim-Chester disease [ECD]) developing after treatment for initial skull LCH is not well ...
Pediatric low‑grade gliomas (pLGGs) have distinct biology and treatment strategies compared to adult gliomas. These Chinese consensus guidelines ...
The U.S. Food and Drug Administration (FDA) has granted plixorafenib a Breakthrough Therapy Designation, signaling accelerated development of this targeted drug for patients with an aggressive ...
CLEVELAND, Ohio — The benefits of getting regular exercise, combining two cancer drugs with chemotherapy, and using AI to ...
Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...
Pall Mall Medical teamed up with Blaze Run Club for this year's 'Poo Protest,' encouraging early detection of bowel cancer ...
Nearly 10,000 cases of advanced bowel cancer are diagnosed in England each year, with cases in young adults rising. There are ...
Heather Kaiser, a 43-year-old attorney and active mom of two, shares the story of her early onset stage 4 colon cancer ...